leisure time -WSS

leisure time

author：focus 2025-09-06 06:16:36 - browse：4424

Are there still too many biotech companies? How do you know when you’re in a bubble? And is there a wrong way to pronounce “TIGIT”?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Josh Schimmer and Eric Schmidt, two longtime analysts teaming up at Cantor Fitzgerald, join us for a back-to-school conversation as biotech enters the busy back third of 2023. We also discuss the latest news in the life sciences, including some scientific evolution at Biogen, new leadership at Illumina, and the future of CRISPR medicine.

For more on what we cover, here’s the news from Biogen; here’s more on Illumina; here’s where you can find episodes of Color Code; and here’s where you can subscribe to the First Opinion Podcast.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： In age of alternative facts, a scholarly course on calling out crap
Next article： CVS is on a mission to consolidate health care. Will it work?

WSS

It's been 20 years since Dolly the sheep. Where's my clone?

What causes osteoarthritis? Researchers study link to brain protein

Changes to biosimilar regulatory framework must prioritize patients

Intarcia’s device

What Congress can do to address the rural doctor shortage

Lasker Awards 2023: Winners in biomedical research

explore

leisure time

Wikipedia

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Pumping milk in bathrooms at health conferences is common

What does generative AI mean for health care? We asked experts

FDA endorses new sterilization method for medical devices

In Memoriam: Notable people who died in 2023

It's been 20 years since Dolly the sheep. Where's my clone?

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

EpiPen alternative approval delay highlights citizen petition issue

Medicare details structure of new drug price negotiation program

Readout Newsletter: Parkinson's study, Gilead, CG Oncology

leisure time

Microsoft launches AI tool for clinical documentation through Epic

It's been 20 years since Dolly the sheep. Where's my clone?

High breast density mammograms need follow

How AI helped researchers track recovery from depression

Update the Apgar Score to remove skin color

TikTok, Instagram influencers need more rules for drug ads

knowledge

focus

explore

leisure time